Algorae Pharmaceuticals Limited has released a press release.
Approval granted for group 3 in Parkinsons trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- US choroid plexus cells patent application published
- Group 2 Parkinsons trial patients treatment completed
- Reinstatement to Official Quotation
- Suspension from Official Quotation
- Approval granted for group 2 in Parkinsons trial
Later from Algorae Pharmaceuticals
- Living Insights Newsletter February 2017
- Treatment completed for all patients in Parkinsons trial
- LCT collaborates with CBR to extend product pipeline
- NTCELL continues to halt progression of Parkinsons disease
- Preliminary Final Report and Financial Statements
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals